Sleep-wake Disorders: Systematic Review of Approved Psychiatric Medications (2008 to 2024) and Pipeline Phase-3 Medications.

IF 2.8 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of Clinical Psychopharmacology Pub Date : 2025-09-01 Epub Date: 2025-08-14 DOI:10.1097/JCP.0000000000002049

Lauren Dugan, Aasim Naqvi, Ashley Ngor, Jayant Totlani, Tiffany Chang, Drew Hirsch, Salma Abdelmoteleb, Thomas Parrish, Piyush Nayyar, Kyla Truman, Michael Irwin, Robert N Pechnick, Itai Danovitch, Waguih W IsHak

{"title":"Sleep-wake Disorders: Systematic Review of Approved Psychiatric Medications (2008 to 2024) and Pipeline Phase-3 Medications.","authors":"Lauren Dugan, Aasim Naqvi, Ashley Ngor, Jayant Totlani, Tiffany Chang, Drew Hirsch, Salma Abdelmoteleb, Thomas Parrish, Piyush Nayyar, Kyla Truman, Michael Irwin, Robert N Pechnick, Itai Danovitch, Waguih W IsHak","doi":"10.1097/JCP.0000000000002049","DOIUrl":null,"url":null,"abstract":"Purpose: This systematic review examines the psychiatric medications approved by the Food and Drug Administration (FDA) for sleep-wake disorders within the past 17 years, from 2008 through 2024, to describe the mechanism of action, indications, evidence for efficacy, dosing, and adverse effects for each medication, as well as the medications that are in the pipeline for approval in phase 3.Methods: Studies published from January 1, 2008, until December 31, 2024, were identified from the PubMed database using the keywords \"sleep*\" AND \"disorder*\" OR \"psychopharm*\" AND \"medic*\" OR \"pharm*.\" An independent, focused analysis was conducted, and a consensus was reached on the studies to be included in this systematic review. Key findings were derived from the full text and tables of the selected studies.Results: From January 1, 2008, to December 31, 2024, the FDA approved 14 medications for sleep-wake disorders and three pipeline medications as of December 31, 2024, currently in phase 3 clinical trials.Conclusions: Through this comprehensive systematic review, stakeholders-including clinicians, researchers, policymakers, and patients-can gain insights into the current treatment landscape and anticipate future therapeutic innovations. This review serves as a resource for guiding treatment decisions and optimizing care for patients with sleep-wake disorders.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"493-505"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCP.0000000000002049","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This systematic review examines the psychiatric medications approved by the Food and Drug Administration (FDA) for sleep-wake disorders within the past 17 years, from 2008 through 2024, to describe the mechanism of action, indications, evidence for efficacy, dosing, and adverse effects for each medication, as well as the medications that are in the pipeline for approval in phase 3.

Methods: Studies published from January 1, 2008, until December 31, 2024, were identified from the PubMed database using the keywords "sleep*" AND "disorder*" OR "psychopharm*" AND "medic*" OR "pharm*." An independent, focused analysis was conducted, and a consensus was reached on the studies to be included in this systematic review. Key findings were derived from the full text and tables of the selected studies.

Results: From January 1, 2008, to December 31, 2024, the FDA approved 14 medications for sleep-wake disorders and three pipeline medications as of December 31, 2024, currently in phase 3 clinical trials.

Conclusions: Through this comprehensive systematic review, stakeholders-including clinicians, researchers, policymakers, and patients-can gain insights into the current treatment landscape and anticipate future therapeutic innovations. This review serves as a resource for guiding treatment decisions and optimizing care for patients with sleep-wake disorders.

查看原文本刊更多论文

睡眠-觉醒障碍：已批准的精神科药物（2008 - 2024）和iii期药物的系统回顾。

目的：本系统综述研究了美国食品和药物管理局（FDA）在过去17年中（从2008年到2024年）批准的用于治疗睡眠-觉醒障碍的精神药物，以描述每种药物的作用机制、适应症、疗效证据、剂量和不良反应，以及正在进行第三阶段批准的药物。方法：从2008年1月1日至2024年12月31日发表的研究，使用关键词“sleep*”和“disorder*”或“psychopharm*”和“medic*”或“pharm*”从PubMed数据库中识别。进行了一项独立的、有重点的分析，并就纳入本系统评价的研究达成了共识。主要研究结果来自所选研究的全文和表格。结果：从2008年1月1日到2024年12月31日，FDA批准了14种治疗睡眠觉醒障碍的药物和3种药物，截至2024年12月31日，目前正在进行3期临床试验。结论：通过这一全面的系统综述，包括临床医生、研究人员、政策制定者和患者在内的利益相关者可以深入了解当前的治疗前景，并预测未来的治疗创新。本综述可作为指导治疗决策和优化睡眠-觉醒障碍患者护理的资源。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Psychopharmacology 医学-精神病学

CiteScore

4.00

自引率

3.40%

发文量

231

审稿时长

4-8 weeks

期刊介绍： Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.